Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Deepcell Garners Industry Recognition for Disruptive AI-Driven Approach to Single Cell Morphology Analysis

Morpholomics builds momentum as Deepcell plans to share data generated by the REM-I platform at upcoming scientific meetings

Deepcell, a pioneer in artificial intelligence (AI)-powered single-cell analysis to fuel deep biological discoveries, shared the news of two significant industry recognitions as it prepares for upcoming scientific meetings. The company plans to share five public datasets from its REM-I platform and demo its Axon data suite at the upcoming annual meeting of the Association of Molecular Pathology (November 14-18, 2023 in Salt Lake City, Utah) and Cell Bio 2023, the joint meeting of the American Society for Cell Biology and European Molecular Biology Organization (December 2-6, 2023 in Boston, Mass.).

Earlier this year, Deepcell launched the REM-I platform, a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, Human Foundation Model, and Axon data suite. By bringing together single cell imaging, sorting, and high-dimensional analysis, the REM-I platform catalyzes new methods of discovery in a wide range of fields including cancer biology, developmental biology, stem cell biology, gene therapy and functional screening, among others.

Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024

AIThority Predictions Series 2024 banner

Unlike microscopy and flow cytometry methods, the REM-I platform offers several unique capabilities for the deep characterization of biological samples, single cells, and the ability to sort cells without the need for labels. By marrying high-resolution imaging of single cells and label-free sorting with artificial intelligence in one platform, the REM-I platform enables a high-throughput, quantitative way to understand and analyze the morphology of cells, unlocking new biotechnological discoveries.

Deepcell CEO Maddison Masaeli Receives Life Science Catalyst Award

Related Posts
1 of 41,287

Maddison Masaeli was recently named as one of ten Life Science Catalyst Award winners by Biocom California, the association representing the California life science industry. The awards celebrate the most inspiring and driven young minds who are sparking meaningful change to human health through research, discovery, and entrepreneurship in California. She and her fellow awardees will be celebrated at the Biocom California’s “Celebration of Life” dinner on November 16, 2023.

Recommended AI News: OSS Unveils New Gen 5 AI Transportable Compute Server

Deepcell REM-I Platform Named Cell Imaging Product of the Year

Deepcell’s REM-I platform was selected as “Cell Imaging Product of the Year,” one of only four breakthrough innovations in the field of cell biology, in the third annual BioTech Breakthrough Awards. The awards program is conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.

Recommended AI News: Ethical Web AI Launches AI Seek 4.0 with Almost Real-Time Data

“These awards are a validation of the significance of AI-based phenotyping to the future of biomedical research, and a testament to the impact of technologies like ours across the life sciences industry,” said Maddison Masaeli, Ph.D., cofounder and chief executive officer at Deepcell. “We look forward to sharing additional data generated with our platform at the annual meetings of the Association of Molecular Pathology and American Society for Cell Biology to continue to demonstrate the robustness of our REM-I platform.”

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.